Omalizumab ameliorates extra-respiratory symptoms in patients with aspirin-exacerbated respiratory disease

Omalizumab, an anti-immunoglobulin E antibody, has clinical efficacy against respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, some patients with AERD also present with extra-respiratory (chest, gastrointestinal, and/or cutaneous) symptoms, which are resistant to conventional treatment but can be alleviated by systemic corticosteroids.

Source: Journal of Allergy and Clinical Immunology - March 24, 2023 Category: Allergy & Immunology Authors: Hiroaki Hayashi, Yuma Fukutomi, Chihiro Mitsui, Keiichi Kajiwara, Kentaro Watai, Yasuhiro Tomita, Yosuke Kamide, Takahiro Tsuburai, Kiyoshi Sekiya, Makoto Ishii, Yoshinori Hasegawa, Masami Taniguchi Source Type: research